Corgenix announces establishment of bio-terrorism defense development program
Corgenix Medical Corporation announced establishment of a program to develop a rapid detection system for viral hemorrhagic fevers, a disease category recognized and classified for its risk as potential agents of bioterrorism. Viral hemorrhagic fevers are included in the high priority "Category A" of biological diseases as defined by the Centers for Disease Control and Prevention (CDC). Along with anthrax, botulism, plague, smallpox and tularemia, viruses causing hemorrhagic fevers have been identified as key targets in the effort to understand and combat potential agents of bioterrorism.
In commenting about this new initiative in bio-terrorism defense diagnostics, Douglass Simpson, Corgenix President said, "This is a logical growth opportunity for Corgenix in a critical area that needs to be addressed on a national and international level. Bio-Terrorism Defense is a very important issue in this day and age, and we are confident that our collaboration with key industry and academic scientists will show meaningful results in a short period of time. We expect to present our program to the CDC, U.S. Department of Defense, and U.S. Department of Homeland Security, among other important government agencies and interested parties."
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
